<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300924</url>
  </required_header>
  <id_info>
    <org_study_id>Merck 075-00</org_study_id>
    <secondary_id>Merk 075-00</secondary_id>
    <nct_id>NCT00300924</nct_id>
  </id_info>
  <brief_title>A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine</brief_title>
  <official_title>A Double-Blind, Double-Dummy, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10mg Co-Administered With Acetaminophen for the Treatment of Acute Migraine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diamond Headache Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Diamond Headache Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test an experimental drug combination of two medications
      currently approved by the Food and Drug Administration (FDA) for migraine headache or other
      pain. These are called rizatriptan given with acetaminophen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the efficacy of rizatriptan co-administered with acetaminophen to placebo, acetaminophen and rizatriptan for the acute treatment of migraine, as measured by the percentage of patients with pain relief at 2 hours.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 hour sustained pain relief</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain relief at 30, 45,60,90 minutes and 4 hours post dose</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain freedom at 30,45,60,90 minutes and 2 and 4 hours post dose</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 sustained pain freedom</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associated symptoms of phonophobia, photophobia, nausea and vomiting</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional disability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported adverse experiences</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>Migraine</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rizatriptan co-administered with Acetaminophen</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is at least 18 years of age

          -  Subject has at least a 6 month history of migraine, with or without aura

          -  Subject can distinguish between migraine attacks and other types of headaches

          -  Subject of childbearing potential agrees to use adequate contraception

        Exclusion Criteria:

          -  Subject typically has fewer than 1 or greater than 6 migraine attacks per month

          -  Subject typically has greater than 10 headache days per month

          -  Subject has evidence of ischemic heart disease

          -  Subject has uncontrolled high blood pressure

          -  Subject has a history, within 1 year, or current evidence of drug or alcohol abuse

        *This list is not all inclusive*
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merle Diamond, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Diamond Headache Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SanFrancisco Headache Clinic</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diamond Headache Clinic</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Family Medical Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinvest</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkind Headache Center</name>
      <address>
        <city>Mount Vernon</city>
        <state>New York</state>
        <zip>10550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinExcel</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2006</study_first_submitted>
  <study_first_submitted_qc>March 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2006</study_first_posted>
  <last_update_submitted>May 27, 2008</last_update_submitted>
  <last_update_submitted_qc>May 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Karin E. Brooks, BSN, RN Director of Clinical Research</name_title>
    <organization>Diamond Headache Clinic</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Rizatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

